HSBC Holdings plc set a €78.00 ($91.76) price target on Sanofi SA (EPA:SAN) in a research report sent to investors on Friday. The brokerage currently has a neutral rating on the stock.

SAN has been the topic of a number of other reports. Morgan Stanley set a €92.00 ($108.24) price target on shares of Sanofi SA and gave the stock a buy rating in a research note on Friday, October 6th. S&P Global set a €90.00 ($105.88) price target on shares of Sanofi SA and gave the stock a neutral rating in a research note on Monday, July 31st. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price target on shares of Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, October 17th. J P Morgan Chase & Co set a €90.00 ($105.88) price target on shares of Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, August 1st. Finally, BNP Paribas set a €85.00 ($100.00) price target on shares of Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, September 12th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company’s stock. Sanofi SA presently has a consensus rating of Hold and an average target price of €87.24 ($102.63).

Sanofi SA (EPA SAN) opened at €79.02 ($92.96) on Friday. Sanofi SA has a 1 year low of €70.94 ($83.46) and a 1 year high of €92.97 ($109.38).

ILLEGAL ACTIVITY WARNING: “HSBC Holdings plc Analysts Give Sanofi SA (SAN) a €78.00 Price Target” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/11/05/hsbc-holdings-plc-analysts-give-sanofi-sa-san-a-78-00-price-target.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.